In today’s recent session, 0.48 million shares of the Axsome Therapeutics Inc (NASDAQ:AXSM) have been traded, and its beta is 1.02. Most recently the company’s share price was $132.49, and it changed around $5.41 or 4.26% from the last close, which brings the market valuation of the company to $6.42B. AXSM at last check was trading at a discount to its 52-week high of $132.25, offering almost 0.18% off that amount. The share price’s 52-week low was $64.11, which indicates that the recent value has risen by an impressive 51.61% since then. We note from Axsome Therapeutics Inc’s average daily trading volume that its 10-day average is 1.25 million shares, with the 3-month average coming to 858.72K.
Axsome Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.07. If we narrow it down even further, the data shows that 0 out of 16 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 0 recommended AXSM as a Hold, whereas 11 deemed it a Buy, and 0 rated it as Underweight. Axsome Therapeutics Inc is expected to report earnings per share of -0.98 for the current quarter.
Axsome Therapeutics Inc (NASDAQ:AXSM) trade information
Instantly AXSM has been showing a green trend so far today with a performance of 4.26% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 134.16 on recent trading dayincreased the stock’s daily price by 1.24%. The company’s shares are currently up 56.59% year-to-date, but still up 17.33% over the last five days. On the other hand, Axsome Therapeutics Inc (NASDAQ:AXSM) is 65.51% up in the 30-day period. We can see from the shorts that 5.75 million shares have been sold at a short interest cover period of 6.08 day(s).
The consensus price target as assigned by Wall Street analysts is $137, which translates to bulls needing to increase their stock price by 3.29% from its current value. Analyst projections state that AXSM is forecast to be at a low of $132 and a high of $190.
Axsome Therapeutics Inc (AXSM) estimates and forecasts
The year-over-year growth rate is expected to be 42.35%, up from the previous year.
Consensus estimates provided by 15 financial analysts predict the company will bring in an average of 118.07M in revenue for the current quarter. 13 analysts expect Axsome Therapeutics Inc to make 122.41M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 71.53M and 75M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 65.06%. Forecasts for the next quarter put sales growth at 63.22%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -35.53%.
AXSM Dividends
Axsome Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Axsome Therapeutics Inc (NASDAQ:AXSM)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 17.06% of Axsome Therapeutics Inc shares, and 81.96% of them are in the hands of institutional investors. The stock currently has a share float of 98.82%. Axsome Therapeutics Inc stock is held by 391.0 institutions, with RTW INVESTMENTS, LP being the largest institutional investor. By 2024-06-30, it held 9.7784% of the shares, which is about 4.63 million shares worth $373.06 million.
VANGUARD GROUP INC, with 7.8956% or 3.74 million shares worth $301.23 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 1.31 shares worth $173.73 million, making up 2.71% of all outstanding shares. On the other hand, Vanguard Small-Cap Index Fund held roughly 1.02 shares worth around $135.29 million, which represents about 2.11% of the total shares outstanding.
